<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686969</url>
  </required_header>
  <id_info>
    <org_study_id>SCGAM-02</org_study_id>
    <nct_id>NCT03686969</nct_id>
  </id_info>
  <brief_title>Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis</brief_title>
  <official_title>Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Dermatomyositis (SCGAM-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY&#xD;
      OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study complexity, low study recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Actual">November 29, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMT-8</measure>
    <time_frame>32 weeks</time_frame>
    <description>MMT-8; a set of 8 designated muscles tested bilaterally [potential score 0 - 150]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CDASI</measure>
    <time_frame>32 weeks</time_frame>
    <description>The CDASI is a clinician-scored single page instrument that separately measures activity and damage in the skin of DM patients for use in clinical practice or clinical/therapeutic studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician's Global Disease Activity VAS Worsening</measure>
    <time_frame>32 weeks</time_frame>
    <description>Physician's Global Disease Activity (10 cm VAS assessing global disease activity from &quot;No evidence of disease activity&quot; to &quot;Extremely active or severe disease activity&quot;; Disease Activity being defined as potentially reversible pathology or physiology resulting from the myositis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extra-Muscular Disease Activity</measure>
    <time_frame>32 weeks</time_frame>
    <description>Extra-muscular activity (part of MDAAT; a combined tool that captures the physician's assessment of disease activity of various organ systems using a scale from 0 = &quot;Not present in the last 4 weeks&quot; to 4 = &quot;New - in the last 4 weeks [compared to the previous 4 weeks]&quot; and a VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Enzymes - Aldolase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Measurement of aldolase in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Enzymes - Creatine Kinase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Measurement of creatine kinase in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Enzymes - Alanine Aminotransferase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Measurement of alanine aminotransferase in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Enzymes - Aspartate Aminotransferase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Measurement of aspartate aminotransferase in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Enzymes - Lactate Dehydrogenase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Measurement of lactate dehydrogenase in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire</measure>
    <time_frame>32 weeks</time_frame>
    <description>• Health Assessment Questionnaire (HAQ; a generic rather than a disease-specific instrument; comprised of 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 [without any difficulty] to 3 [unable to do]. For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 Health Survey</measure>
    <time_frame>32 weeks</time_frame>
    <description>The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in TIS</measure>
    <time_frame>32 weeks</time_frame>
    <description>Total Improvement Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinically Important Deterioration</measure>
    <time_frame>32 weeks</time_frame>
    <description>Time to clinically important deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>32 weeks</time_frame>
    <description>Occurrence of all adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TEEs</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety with occurrence of all thromboembolic events (TEEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HTRs</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety with occurrence of all hemolytic transfusion reactions (HTRs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Site Reactions</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety by assessing local injection site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through blood pressure values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through heart rate values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through body temperature values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through respiratory rate values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>32 Weeks</time_frame>
    <description>The physical examination outcome will be analyzed based on changes from baseline as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab sodium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab potassium levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALAT</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab ALAT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAT</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab ASAT levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab LDH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab total bilirubin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab blood urea nitrogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urea levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab creatinine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab hematocrit levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab hemoglobin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Count</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab red blood cell count levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Blood Cell Count</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab white blood cell count levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab platelet levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Haptoglobin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab serum haptoglobin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma-Free Hemoglobin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab plasma-free hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Coombs' Test</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through Direct Coombs' test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimers</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through D-dimers test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IgG</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab IgG levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldolase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab aldolase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine Kinase</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab creatine kinase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Test</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through pregnancy test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Protein</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Glucose</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pH</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine pH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Nitrite</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine nitrite levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Ketones</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine ketone levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Leukocytes</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine leukocyte levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Hemoglobin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine hemoglobin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Bilirubin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine bilirubin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Urobilinogen</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine urobilinogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Hemosiderin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through lab urine hemosiderin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through HIV testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through hepatitis B testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis C</measure>
    <time_frame>32 weeks</time_frame>
    <description>Monitoring safety through hepatitis C testing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Octanorm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5g/kg/week octanorm 16.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octanorm</intervention_name>
    <description>Octanorm 0.5g/kg/week</description>
    <arm_group_label>Octanorm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with diagnosis of definite or probable DM according to the Bohan and Peter&#xD;
             criteria.&#xD;
&#xD;
          2. Subjects who have responded to IGIV treatment as assessed by the treating physician&#xD;
             and being on a stable dose for at least 3 months on 2 g/kg bodyweight (+/- 10%).&#xD;
&#xD;
          3. For subjects being on other medication(s) for the treatment of DM (immunosuppressants,&#xD;
             corticosteroids): a) subject was on such medication(s) at the start of IGIV treatment&#xD;
             in the first place, and b) received such medication(s) for at least 3 months prior to&#xD;
             study enrolment and at a stable dose for at least 4 weeks prior to study enrolment at&#xD;
             the maximally allowed conditions as per Table 2 (see section 4.2.1).&#xD;
&#xD;
          4. MMT-8 score ≥144, with at least 3 other CSM to be normal or near normal as per the&#xD;
             following criteria: Visual Analogue Scale [VAS] of patient global disease activity ≤2&#xD;
             cm, physician's global disease activity ≤2 cm, extra-muscular disease activity ≤2 cm;&#xD;
             no muscle enzyme &gt;4 times upper limit of normal due to myositis, Health Assessment&#xD;
             Questionnaire [HAQ] ≤0.25.&#xD;
&#xD;
          5. Males or females ≥ 18 to &lt;80 years of age.&#xD;
&#xD;
          6. Voluntarily given, fully informed written consent obtained from subject before any&#xD;
             study-related procedures are conducted.&#xD;
&#xD;
          7. Subject must be capable and willing to understand and comply with the relevant aspects&#xD;
             of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cancer-associated myositis, defined as the diagnosis of myositis within 2 years of the&#xD;
             diagnosis of cancer (except basal or squamous cell skin cancer or carcinoma in situ of&#xD;
             the cervix that has been excised and cured and at least 1 or 5 years, respectively,&#xD;
             have passed since excision).&#xD;
&#xD;
          2. Evidence of active malignant disease or malignancies diagnosed within the previous 5&#xD;
             years (including hematological malignancies and solid tumors) or breast cancer&#xD;
             diagnosed within the previous 10 years. Subjects &gt;5 years (&gt;10 years for breast&#xD;
             cancer) of cancer diagnosis who have been treated and are in remission are allowed.&#xD;
&#xD;
          3. Subjects with overlap myositis (except for overlap with Sjögren's syndrome),&#xD;
             connective tissue disease associated DM, inclusion body myositis, polymyositis or&#xD;
             drug-induced myopathy.&#xD;
&#xD;
          4. Subjects with immune-mediated necrotizing myopathy with absence of typical DM rash.&#xD;
&#xD;
          5. Subjects with generalized, severe musculoskeletal conditions other than DM that&#xD;
             prevent a sufficient assessment of the subject by the physician.&#xD;
&#xD;
          6. Subjects who received blood or plasma-derived products (other than IGIV) or plasma&#xD;
             exchange within the last 3 months before enrolment.&#xD;
&#xD;
          7. Subjects with administration of permitted concomitant medications exceeding the&#xD;
             maximally allowed conditions as per section 4.2.1.&#xD;
&#xD;
          8. Subjects with administration of forbidden concomitant medications within the washout&#xD;
             periods as defined in Table 3: see section 4.2.2.&#xD;
&#xD;
          9. Subjects starting or planning to start a physical therapy-directed exercise regimen&#xD;
             during the trial. Subjects on stable physical therapy for &gt;4 weeks are allowed but the&#xD;
             regimen should remain the same throughout the trial.&#xD;
&#xD;
         10. Cardiac insufficiency (New York Heart Association III/IV), cardiomyopathy, significant&#xD;
             cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease.&#xD;
&#xD;
         11. Severe liver disease, with signs of ascites and hepatic encephalopathy.&#xD;
&#xD;
         12. Severe kidney disease (as defined by estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
             mL/min/1.73 m2).&#xD;
&#xD;
         13. Known hepatitis B, hepatitis C or HIV infection.&#xD;
&#xD;
         14. Subjects with a history of deep vein thrombosis within the last year prior to study&#xD;
             enrolment or pulmonary embolism ever.&#xD;
&#xD;
         15. Body mass index &gt;40 kg/m2 and/or body weight &gt;120 kg.&#xD;
&#xD;
         16. Medical conditions whose symptoms and effects could alter protein catabolism and/or&#xD;
             IgG utilization (e.g. protein-losing enteropathies, nephrotic syndrome).&#xD;
&#xD;
         17. Known IgA deficiency with antibodies to IgA.&#xD;
&#xD;
         18. History of hypersensitivity, anaphylaxis or severe systemic response to&#xD;
             immunoglobulin, blood or plasma derived products or any component of octanorm 16.5%&#xD;
             such as polysorbate 80 or to sodium chloride.&#xD;
&#xD;
         19. Known blood hyperviscosity, or other hypercoagulable states.&#xD;
&#xD;
         20. Subjects with a history of drug abuse within the past 5 years prior to study&#xD;
             enrolment.&#xD;
&#xD;
         21. Participating in another interventional clinical study with investigational treatment&#xD;
             within 3 months prior to study enrolment. Subjects who participated in the Octagam 10%&#xD;
             Dermatomyositis Study (GAM10-08) can be included.&#xD;
&#xD;
         22. Women who are breast feeding, pregnant, or planning to become pregnant, or are&#xD;
             unwilling to apply an effective birth control method (as per protocol section 7.3.9 b)&#xD;
             up to four weeks after the last IMP infusion received.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>I.M. SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY Rheumatology Department Of, Clinici Of Nephrology</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>April 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2021</results_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03686969/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03686969/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Octanorm</title>
          <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Early study termination.</population>
      <group_list>
        <group group_id="B1">
          <title>Octanorm</title>
          <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MMT-8</title>
        <description>MMT-8; a set of 8 designated muscles tested bilaterally [potential score 0 - 150]</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>MMT-8</title>
          <description>MMT-8; a set of 8 designated muscles tested bilaterally [potential score 0 - 150]</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CDASI</title>
        <description>The CDASI is a clinician-scored single page instrument that separately measures activity and damage in the skin of DM patients for use in clinical practice or clinical/therapeutic studies.</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>CDASI</title>
          <description>The CDASI is a clinician-scored single page instrument that separately measures activity and damage in the skin of DM patients for use in clinical practice or clinical/therapeutic studies.</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physician's Global Disease Activity VAS Worsening</title>
        <description>Physician's Global Disease Activity (10 cm VAS assessing global disease activity from &quot;No evidence of disease activity&quot; to &quot;Extremely active or severe disease activity&quot;; Disease Activity being defined as potentially reversible pathology or physiology resulting from the myositis).</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Disease Activity VAS Worsening</title>
          <description>Physician's Global Disease Activity (10 cm VAS assessing global disease activity from &quot;No evidence of disease activity&quot; to &quot;Extremely active or severe disease activity&quot;; Disease Activity being defined as potentially reversible pathology or physiology resulting from the myositis).</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extra-Muscular Disease Activity</title>
        <description>Extra-muscular activity (part of MDAAT; a combined tool that captures the physician's assessment of disease activity of various organ systems using a scale from 0 = &quot;Not present in the last 4 weeks&quot; to 4 = &quot;New - in the last 4 weeks [compared to the previous 4 weeks]&quot; and a VAS).</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Extra-Muscular Disease Activity</title>
          <description>Extra-muscular activity (part of MDAAT; a combined tool that captures the physician's assessment of disease activity of various organ systems using a scale from 0 = &quot;Not present in the last 4 weeks&quot; to 4 = &quot;New - in the last 4 weeks [compared to the previous 4 weeks]&quot; and a VAS).</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Enzymes - Aldolase</title>
        <description>Measurement of aldolase in blood</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Enzymes - Aldolase</title>
          <description>Measurement of aldolase in blood</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Enzymes - Creatine Kinase</title>
        <description>Measurement of creatine kinase in blood</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Enzymes - Creatine Kinase</title>
          <description>Measurement of creatine kinase in blood</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Enzymes - Alanine Aminotransferase</title>
        <description>Measurement of alanine aminotransferase in blood</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Enzymes - Alanine Aminotransferase</title>
          <description>Measurement of alanine aminotransferase in blood</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Enzymes - Aspartate Aminotransferase</title>
        <description>Measurement of aspartate aminotransferase in blood</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Enzymes - Aspartate Aminotransferase</title>
          <description>Measurement of aspartate aminotransferase in blood</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Enzymes - Lactate Dehydrogenase</title>
        <description>Measurement of lactate dehydrogenase in blood</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Enzymes - Lactate Dehydrogenase</title>
          <description>Measurement of lactate dehydrogenase in blood</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire</title>
        <description>• Health Assessment Questionnaire (HAQ; a generic rather than a disease-specific instrument; comprised of 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 [without any difficulty] to 3 [unable to do]. For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8).</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire</title>
          <description>• Health Assessment Questionnaire (HAQ; a generic rather than a disease-specific instrument; comprised of 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 [without any difficulty] to 3 [unable to do]. For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8).</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36v2 Health Survey</title>
        <description>The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36v2 Health Survey</title>
          <description>The SF-36 is a multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index.</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in TIS</title>
        <description>Total Improvement Score</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in TIS</title>
          <description>Total Improvement Score</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinically Important Deterioration</title>
        <description>Time to clinically important deterioration</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinically Important Deterioration</title>
          <description>Time to clinically important deterioration</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Occurrence of all adverse events</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Occurrence of all adverse events</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TEEs</title>
        <description>Monitoring safety with occurrence of all thromboembolic events (TEEs)</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TEEs</title>
          <description>Monitoring safety with occurrence of all thromboembolic events (TEEs)</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HTRs</title>
        <description>Monitoring safety with occurrence of all hemolytic transfusion reactions (HTRs)</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HTRs</title>
          <description>Monitoring safety with occurrence of all hemolytic transfusion reactions (HTRs)</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Injection Site Reactions</title>
        <description>Monitoring safety by assessing local injection site reactions</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Injection Site Reactions</title>
          <description>Monitoring safety by assessing local injection site reactions</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Monitoring safety through blood pressure values</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Monitoring safety through blood pressure values</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <description>Monitoring safety through heart rate values</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Monitoring safety through heart rate values</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature</title>
        <description>Monitoring safety through body temperature values</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Monitoring safety through body temperature values</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Rate</title>
        <description>Monitoring safety through respiratory rate values</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate</title>
          <description>Monitoring safety through respiratory rate values</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination</title>
        <description>The physical examination outcome will be analyzed based on changes from baseline as adverse events.</description>
        <time_frame>32 Weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Examination</title>
          <description>The physical examination outcome will be analyzed based on changes from baseline as adverse events.</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sodium</title>
        <description>Monitoring safety through lab sodium levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sodium</title>
          <description>Monitoring safety through lab sodium levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potassium</title>
        <description>Monitoring safety through lab potassium levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Potassium</title>
          <description>Monitoring safety through lab potassium levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose</title>
        <description>Monitoring safety through lab glucose levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>Monitoring safety through lab glucose levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALAT</title>
        <description>Monitoring safety through lab ALAT levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ALAT</title>
          <description>Monitoring safety through lab ALAT levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ASAT</title>
        <description>Monitoring safety through lab ASAT levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>ASAT</title>
          <description>Monitoring safety through lab ASAT levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDH</title>
        <description>Monitoring safety through lab LDH levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LDH</title>
          <description>Monitoring safety through lab LDH levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin</title>
        <description>Monitoring safety through lab total bilirubin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin</title>
          <description>Monitoring safety through lab total bilirubin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Urea Nitrogen</title>
        <description>Monitoring safety through lab blood urea nitrogen levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen</title>
          <description>Monitoring safety through lab blood urea nitrogen levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urea</title>
        <description>Monitoring safety through lab urea levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urea</title>
          <description>Monitoring safety through lab urea levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine</title>
        <description>Monitoring safety through lab creatinine levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine</title>
          <description>Monitoring safety through lab creatinine levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin</title>
        <description>Monitoring safety through lab albumin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Albumin</title>
          <description>Monitoring safety through lab albumin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematocrit</title>
        <description>Monitoring safety through lab hematocrit levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hematocrit</title>
          <description>Monitoring safety through lab hematocrit levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin</title>
        <description>Monitoring safety through lab hemoglobin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>Monitoring safety through lab hemoglobin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Red Blood Cell Count</title>
        <description>Monitoring safety through lab red blood cell count levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell Count</title>
          <description>Monitoring safety through lab red blood cell count levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>White Blood Cell Count</title>
        <description>Monitoring safety through lab white blood cell count levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>White Blood Cell Count</title>
          <description>Monitoring safety through lab white blood cell count levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelets</title>
        <description>Monitoring safety through lab platelet levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Platelets</title>
          <description>Monitoring safety through lab platelet levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Haptoglobin</title>
        <description>Monitoring safety through lab serum haptoglobin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Haptoglobin</title>
          <description>Monitoring safety through lab serum haptoglobin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma-Free Hemoglobin</title>
        <description>Monitoring safety through lab plasma-free hemoglobin</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma-Free Hemoglobin</title>
          <description>Monitoring safety through lab plasma-free hemoglobin</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direct Coombs' Test</title>
        <description>Monitoring safety through Direct Coombs' test</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Coombs' Test</title>
          <description>Monitoring safety through Direct Coombs' test</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-dimers</title>
        <description>Monitoring safety through D-dimers test</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>D-dimers</title>
          <description>Monitoring safety through D-dimers test</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum IgG</title>
        <description>Monitoring safety through lab IgG levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum IgG</title>
          <description>Monitoring safety through lab IgG levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aldolase</title>
        <description>Monitoring safety through lab aldolase levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Aldolase</title>
          <description>Monitoring safety through lab aldolase levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatine Kinase</title>
        <description>Monitoring safety through lab creatine kinase levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Creatine Kinase</title>
          <description>Monitoring safety through lab creatine kinase levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pregnancy Test</title>
        <description>Monitoring safety through pregnancy test</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Test</title>
          <description>Monitoring safety through pregnancy test</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Protein</title>
        <description>Monitoring safety through lab urine protein levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Protein</title>
          <description>Monitoring safety through lab urine protein levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Glucose</title>
        <description>Monitoring safety through lab urine glucose levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Glucose</title>
          <description>Monitoring safety through lab urine glucose levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine pH</title>
        <description>Monitoring safety through lab urine pH levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine pH</title>
          <description>Monitoring safety through lab urine pH levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Nitrite</title>
        <description>Monitoring safety through lab urine nitrite levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Nitrite</title>
          <description>Monitoring safety through lab urine nitrite levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Ketones</title>
        <description>Monitoring safety through lab urine ketone levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Ketones</title>
          <description>Monitoring safety through lab urine ketone levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Leukocytes</title>
        <description>Monitoring safety through lab urine leukocyte levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Leukocytes</title>
          <description>Monitoring safety through lab urine leukocyte levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Hemoglobin</title>
        <description>Monitoring safety through lab urine hemoglobin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Hemoglobin</title>
          <description>Monitoring safety through lab urine hemoglobin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Bilirubin</title>
        <description>Monitoring safety through lab urine bilirubin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Bilirubin</title>
          <description>Monitoring safety through lab urine bilirubin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Urobilinogen</title>
        <description>Monitoring safety through lab urine urobilinogen levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Urobilinogen</title>
          <description>Monitoring safety through lab urine urobilinogen levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Hemosiderin</title>
        <description>Monitoring safety through lab urine hemosiderin levels</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Hemosiderin</title>
          <description>Monitoring safety through lab urine hemosiderin levels</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV</title>
        <description>Monitoring safety through HIV testing</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>HIV</title>
          <description>Monitoring safety through HIV testing</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis B</title>
        <description>Monitoring safety through hepatitis B testing</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis B</title>
          <description>Monitoring safety through hepatitis B testing</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatitis C</title>
        <description>Monitoring safety through hepatitis C testing</description>
        <time_frame>32 weeks</time_frame>
        <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Octanorm</title>
            <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatitis C</title>
          <description>Monitoring safety through hepatitis C testing</description>
          <population>The study was terminated prematurely. Due to the limited data available (only one patient enrolled and treated), efficacy and safety analyses were not performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The patient was treated according to the protocol until week 14 Treatment after week 14 was discontinued because of early study termination</time_frame>
      <desc>Number of patients at risk for SAEs, All-Cause Mortality, and other adverse events in placebo group is 0 as 0 patients were enrolled into the placebo group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Octanorm</title>
          <description>0.5g/kg/week octanorm 16.5%&#xD;
Octanorm: Octanorm 0.5g/kg/week</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Aldolase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikaela Raymond</name_or_title>
      <organization>CRMG</organization>
      <phone>866-337-1868</phone>
      <email>ctgov@cllinicalresearchmgt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

